Pilot Study of Aprepitant for Prevention of Post-ERCP Pancreatitis in High Risk Patients: A Phase II Randomized, Double-Blind Placebo Controlled Trial
Abstract
Objectives Animal studies have demonstrated a role for substance P binding to neurokinin-1 receptor in the pathogenesis of acute pancreatitis. Our aim was to assess the efficacy of a neurokinin-1 receptor antagonist (aprepitant) at preventing post-ERCP pancreatitis in high risk patients. Design Randomized, double-blind, placebo controlled trial at a single academic medical center. Intervention Patients at high risk for post-ERCP pancreatitis received either placebo or oral aprepitant administered 4 hours prior to ERCP, 80 mg 24 hours after the first dose, and then 80 mg 24 hours after the second dose. Patients Thirty-four patients received aprepitant and 39 patients received placebo. Statistics Fisher’s exact test was used to compare incidence of post-ERCP pancreatitis in the two groups. Results Baseline characteristics were similar between the two groups. Incidence of acute pancreatitis was 7 in the aprepitant group and 7 in the placebo group. Hospitalization within 7 days post-procedure for abdominal pain that did not meet criteria for acute pancreatitis occurred in 6 and 9 patients in the aprepitant and placebo groups respectively (P=0.772). Conclusions Aprepitant did not lower incidence of post-ERCP pancreatitis in this preliminary human study. Larger studies potentially using the recently available intravenous formulation are necessary to conclusively clarify the efficacy of aprepitant in this setting.
Image: Duke University School of Medicine. Durham, VA, USA.
Downloads
References
Mallery, J.S., et al., Complications of ERCP. Gastrointest Endosc, 2003. 57(6): p. 633-8.
Freeman, M.L., et al., Complications of endoscopic biliary sphincterotomy. N Engl J Med, 1996. 335(13): p. 909-18.
Loperfido, S., et al., Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc, 1998. 48(1): p. 1-10.
Andriulli, A., et al., Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol, 2007. 102(8): p. 1781-8.
Akashi, R., et al., Mechanism of pancreatitis caused by ERCP. Gastrointest Endosc, 2002. 55(1): p. 50-4.
Cheon, Y.K., et al., Frequency and severity of post-ERCP pancreatitis correlated with extent of pancreatic ductal opacification. Gastrointest Endosc, 2007. 65(3): p. 385-93.
Pezzilli, R., et al., Mechanisms involved in the onset of post-ERCP pancreatitis. JOP, 2002. 3(6): p. 162-8.
Raty, S., et al., Post-ERCP pancreatitis: reduction by routine antibiotics. J Gastrointest Surg, 2001. 5(4): p. 339-45; discussion 345.
Mazaki, T., H. Masuda, and T. Takayama, Prophylactic pancreatic stent placement and post-ERCP pancreatitis: a systematic review and meta-analysis. Endoscopy, 2010. 42(10): p. 842-53.
Singh, P., et al., Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. Gastrointest Endosc, 2004. 60(4): p. 544-50.
Sofuni, A., et al., Prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis by an endoscopic pancreatic spontaneous dislodgement stent. Clin Gastroenterol Hepatol, 2007. 5(11): p. 1339-46.
Zheng, M., et al., Meta-analysis of prophylactic allopurinol use in post-endoscopic retrograde cholangiopancreatography pancreatitis. Pancreas, 2008. 37(3): p. 247-53.
Rabenstein, T., et al., Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. Gastrointest Endosc, 2004. 59(6): p. 606-13.
Kapetanos, D., et al., A randomized controlled trial of pentoxifylline for the prevention of post-ERCP pancreatitis. Gastrointest Endosc, 2007. 66(3): p. 513-8.
Bang, U.C., et al., Meta-analysis: Nitroglycerin for prevention of post-ERCP pancreatitis. Aliment Pharmacol Ther, 2009. 29(10): p. 1078-85.
Chen, B., T. Fan, and C.H. Wang, A meta-analysis for the effect of prophylactic GTN on the incidence of post-ERCP pancreatitis and on the successful rate of cannulation of bile ducts. BMC Gastroenterol, 2010. 10: p. 85.
Elmunzer, B.J., et al., A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut, 2008. 57(9): p. 1262-7.
Dai, H.F., X.W. Wang, and K. Zhao, Role of nonsteroidal anti-inflammatory drugs in the prevention of post-ERCP pancreatitis: a meta-analysis. Hepatobiliary Pancreat Dis Int, 2009. 8(1): p. 11-6.
Tsujino, T., T. Kawabe, and M. Omata, Antiproteases in preventing post-ERCP acute pancreatitis. JOP, 2007. 8(4 Suppl): p. 509-17.
Jowell, P.S., et al., Intravenous synthetic secretin reduces the incidence of pancreatitis induced by endoscopic retrograde cholangiopancreatography. Pancreas, 2011. 40(4): p. 533-9.
Andriulli, A., et al., Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc, 2007. 65(4): p. 624-32.
Nathan, J.D., et al., Capsaicin vanilloid receptor-1 mediates substance P release in experimental pancreatitis. Am J Physiol Gastrointest Liver Physiol, 2001. 281(5): p. G1322-8.
Nathan, J.D., et al., Primary sensory neurons: a common final pathway for inflammation in experimental pancreatitis in rats. Am J Physiol Gastrointest Liver Physiol, 2002. 283(4): p. G938-46.
Bhatia, M., et al., Role of substance P and the neurokinin 1 receptor in acute pancreatitis and pancreatitis-associated lung injury. Proc Natl Acad Sci U S A, 1998. 95(8): p. 4760-5.
Baluk, P., et al., NK1 receptors mediate leukocyte adhesion in neurogenic inflammation in the rat trachea. Am J Physiol, 1995. 268(2 Pt 1): p. L263-9.
He, Z.J., et al., Intraductal administration of an NK1 receptor antagonist attenuates the inflammatory response to retrograde infusion of radiological contrast in rats: implications for the pathogenesis and prevention of ERCP-induced pancreatitis. Pancreas, 2003. 27(1): p. e13-7.
Jin, Y., et al., Efficacy and safety of aprepitant in the prevention of chemotherapy-induced nausea and vomiting: a pooled analysis. Support Care Cancer, 2011.
Basch, E., et al., Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol, 2011.
Hargreaves, R., et al., Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann N Y Acad Sci, 2011. 1222: p. 40-8.
Cotton, P.B., et al., Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc, 1991. 37(3): p. 383-93.
Liddle, R.A. and J.D. Nathan, Neurogenic inflammation and pancreatitis. Pancreatology, 2004. 4(6): p. 551-9; discussion 559-60.
Noble, M.D., et al., A pH-sensitive, neurogenic pathway mediates disease severity in a model of post-ERCP pancreatitis. Gut, 2008. 57(11): p. 1566-71.
Shrikhande, S.V., et al., NK-1 receptor gene expression is related to pain in chronic pancreatitis. Pain, 2001. 91(3): p. 209-17.
Copyright (c) 2014 Tilak Upendra Shah, Rodger Liddle, M Stanley Branch, Paul Jowell, Jorge Obando, Martin Poleski
This work is licensed under a Creative Commons Attribution 4.0 International License.
As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.